Autoimmune Uveitis Market Projected to Reach 7% Annual Growth by 2036

In 2025, the market across the seven major pharmaceutical regions—the United States, the EU4, the United Kingdom, and Japan—was valued at approximately USD 1.2 billion. Biologics currently dominate this landscape, accounting for roughly USD 800 million of that total. With nearly 673,000 diagnosed cases identified in 2025, the demand for safer, targeted immunomodulatory therapies has become a primary focus for developers aiming to mitigate complications such as glaucoma and cataracts associated with traditional steroid use.

Innovation is currently centered on a new generation of pipeline candidates. Companies including Priovant Therapeutics, Tarsier Pharma, and Chugai Pharmaceutical are advancing therapies like brepocitinib, TRS01, and RAY121. These treatments target specific inflammatory pathways, such as JAK/TYK2 inhibitors, to offer more durable and personalized care. As these candidates progress through late-stage clinical trials, they are expected to challenge the existing standard of care and fill gaps left by traditional immunosuppressive agents.